ResearcherUniversity of TorontoNo recent work listed
Mitchell A. Winnik
Matched on ORCID iD 0000-0002-2673-2141; OpenAlex author ID A5026093276. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper
Papers 5
- Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or β-parti… Co-author DOI 10.1186/s41181-020-00111-y↗
- Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers Complexed to 177Lu. Co-author DOI 10.1021/acs.molpharmaceut.8b01040↗
- Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111In and 177Lu-An EGFR-Targeted Theranostic for Pancreatic Cancer. Co-author DOI 10.1021/acs.molpharmaceut.7b01000↗
- EGFR-Targeted Metal Chelating Polymers (MCPs) Harboring Multiple Pendant PEG2K Chains for MicroPET/CT Imaging of Patient-Derived Pancreatic Cancer Xenografts. Last author DOI 10.1021/acsbiomaterials.6b00649↗
- MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F… Co-author DOI 10.1016/j.nucmedbio.2014.10.009↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- David William Hedley · 5 shared papers, 2015–2020 · strength 0.51
- Paper Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with A… DOI 10.1186/s41181-020-00111-y↗
- Paper Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelat… DOI 10.1021/acs.molpharmaceut.8b01040↗
- Paper Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111In and 177Lu-An EGFR-Targeted Theranostic for … DOI 10.1021/acs.molpharmaceut.7b01000↗
- Raymond M. Reilly · 5 shared papers, 2015–2020 · strength 0.51
- Paper Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with A… DOI 10.1186/s41181-020-00111-y↗
- Paper Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelat… DOI 10.1021/acs.molpharmaceut.8b01040↗
- Paper Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111In and 177Lu-An EGFR-Targeted Theranostic for … DOI 10.1021/acs.molpharmaceut.7b01000↗
- Sadaf Aghevlian · 3 shared papers, 2018–2020 · strength 0.37
- Paper Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with A… DOI 10.1186/s41181-020-00111-y↗
- Paper Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelat… DOI 10.1021/acs.molpharmaceut.8b01040↗
- Paper Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111In and 177Lu-An EGFR-Targeted Theranostic for … DOI 10.1021/acs.molpharmaceut.7b01000↗
- Yijie Lu · 3 shared papers, 2017–2019 · strength 0.30
- Paper Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelat… DOI 10.1021/acs.molpharmaceut.8b01040↗
- Paper Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111In and 177Lu-An EGFR-Targeted Theranostic for … DOI 10.1021/acs.molpharmaceut.7b01000↗
- Paper EGFR-Targeted Metal Chelating Polymers (MCPs) Harboring Multiple Pendant PEG2K Chains for MicroPET/CT Imaging of Patien… DOI 10.1021/acsbiomaterials.6b00649↗
- Amanda J. Boyle · 2 shared papers, 2015–2017 · strength 0.14
- Paper EGFR-Targeted Metal Chelating Polymers (MCPs) Harboring Multiple Pendant PEG2K Chains for MicroPET/CT Imaging of Patien… DOI 10.1021/acsbiomaterials.6b00649↗
- Paper MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-s… DOI 10.1016/j.nucmedbio.2014.10.009↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.